NEWS & RESOURCES
First Randomized Controlled Study with RejuvenAir® for Chronic Bronchitis shows Clinically Significant Results
Metered Cryospray treats damaged airways enabling a rejuvenative healing response BOSTON, Sept. 6, 2022 /PRNewswire/ -- CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the RejuvenAir®...
CSA Medical Announces Completion of Enrollment in Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis
All subjects have been enrolled in the RejuvenAir System study Characterizing the Mechanism of Action of Metered Cryospray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis.
CSA Medical, Inc. Announces Cooper University Health Care is the 20th Clinical Site to Join the SPRAY-CB Pivotal Study for the treatment of Chronic Bronchitis
Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic Bronchitis.
CSA Medical Announces Metered Cryospray with the RejuvenAir® System for the treatment of Chronic Bronchitis Featured at the 21st World Congress of Bronchology and Interventional Pulmonology
CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the treatment of Chronic Bronchitis was featured in multiple presentations at the 21st World Congress of Bronchology and Interventional Pulmonology in Shanghai
CSA Medical Announces Enrollment Milestone in a Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis
Professor Pallav Shah, M.D., F.R.C.P. from the Royal Brompton, London, is principal investigator of a 32 patient study, characterizing the mechanism of action of Metered Cryospray (MCS) with the RejuvenAir System in patients with Chronic Bronchitis.
CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis
CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis. The SPRAY-CB trial marks the first pivotal study of a medical device therapy targeting the underlying cause of Chronic Bronchitis.
CSA Medical announced this week that it won CE Mark approval for its RejuvenAir system for treating chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB).
Metered CryosprayTM: a novel uniform, controlled, and consistent in vivo application of liquid nitrogen cryogenic spray.
CSA Medical Presents Positive Feasibility Study Results for its RejuvenAir® System at the 2019 European Respiratory Society International Congress
Results demonstrate a strong safety profile and clinically meaningful improvement in quality of life measures in chronic bronchitis patients at 12-month follow-up
RejuvenAir® recently achieved Breakthrough Device Designation by the U.S. FDA and will begin a U.S. Pivotal Study in 2020
CSA Medical said today that results of its feasibility study into the RejuvenAir metered cryospray system showed improved quality of life in patients who have chronic obstructive pulmonary disease with chronic bronchitis.